openPR Logo
Press release

Lawsuit filed for Investors in shares of Celsion Corporation (NASDAQ: CLSN)

11-05-2020 07:44 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Celsion Corporation (NASDAQ: CLSN) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Celsion Corporation (NASDAQ: CLSN) shares over alleged securities laws violations.

An investor, who purchased shares of Celsion Corporation (NASDAQ: CLSN), filed a lawsuit over alleged violations of Federal Securities Laws by Celsion Corporation.

Investors who purchased shares of Celsion Corporation (NASDAQ: CLSN) have certain options and for certain investors are short and strict deadlines running. Deadline: December 28, 2020. NASDAQ: CLSN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lawrenceville, NJ based Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Celsion's lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.

In February 2014, Celsion Corporation announced that the U.S. Food and Drug Administration ("FDA") had reviewed and provided clearance for the Company's planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation ("RFA") in primary liver cancer, also known as hepatocellular carcinoma ("HCC"), called the "OPTIMA Study." The trial design was purportedly based on a comprehensive analysis of data from the Company's Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival ("OS") in a substantial number of HCC patients that received an optimized RFA treatment.
The OPTIMA Study was expected to enroll 550 patients globally, with up to 100 sites in the U.S., Europe, China and Asia Pacific, to evaluate ThermoDox in combination with RFA. The primary endpoint for the trial was OS, and the statistical plan called for two interim efficacy analyses by an independent Data Monitoring Committee ("DMC").
On July 13, 2020, Celsion Corporation announced that "it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer." According to the Company, "[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020," which "found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903."

Shares of Celsion Corporation (NASDAQ: CLSN) declined from $6.5 per share on June 17, 2020 to as low $0.47 per share on October 30, 2020.

The plaintiff claims that between November 2, 2015 and July 10, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that Defendants had significantly overstated the efficacy of ThermoDox, that the foregoing significantly diminished the approval and commercialization prospects for ThermoDox, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Celsion Corporation (NASDAQ: CLSN) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Celsion Corporation (NASDAQ: CLSN) here

News-ID: 2181847 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Celsion

North America Liposome Drug Delivery Market Analysis and Experts Review Report 2 …
The report presents an in-depth assessment of the 'North America Liposome Drug Delivery Market'. This includes enabling demand, key trends, market drivers, challenges, competition, standardization, regulatory landscape, deployment models, competitive analysis, operator case studies, opportunities, future trends, value chains, ecosystem player profiles, and strategies included. The report also presents a SWOT analysis and forecast for North America Liposome Drug Delivery investments from 2019 to 2027. "The North America Liposome Drug Delivery
Liposome Drug Delivery Market to Hit US$ 6,992.95 million , Globally, by 2027 at …
According to the new market research study of "Liposome Drug Delivery Market Forecast to 2027 - the market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow with a CAGR of 8.8% from 2020 to 2027. The liposome drug delivery market majorly consists of players such as Takeda Pharmaceutical Company Limited, Novartis AG, Luye Pharma Group, Ipsen Pharma, Celsion,
Celsion Corporation (NASDAQ: CLSN) Long Term Investor Notice: Investigation of p …
An investigation was announced over possible breaches of fiduciary duties by certain directors and officers of Celsion Corporation. Investors who are current long term investors in Celsion Corporation (NASDAQ: CLSN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: CLSN stocks follows a lawsuit filed against Celsion Corporation over alleged securities laws
Deadline on Dec. 28th coming up in Lawsuit filed for Investors in Celsion Corpor …
A deadline is coming up on December 28, 2020 in the lawsuit filed for certain investors of Celsion Corporation (NASDAQ: CLSN) over alleged securities laws violations by Celsion Corporation. Investors who purchased shares of Celsion Corporation (NASDAQ: CLSN) have certain options and there are strict and short deadlines running. Deadline: December 28, 2020. NASDAQ: CLSN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Cancer Nanomedicine Market Share, Size: Global Growth, Incremental Revenue, Oppo …
The latest release from DBMR highlights the key market trends impacting the growth of the Global Cancer Nanomedicine Market. This report provides information regarding Cancer Nanomedicine market size, trends, growth, cost structure, capacity, revenue and forecast 2027.The report explains the moves of top market players and brands that range from developments, product launches, acquisitions, mergers, joint ventures, trending innovation and business policies. The study highlights influencing factors that are impacting
Liposomes Drug Delivery Market Key Player Analysis By - Gilead Sciences, Pacira, …
The demand for Liposomes Drug Delivery Industry is anticipated to be high for the next six years. By considering this demand we provide latest Liposomes Drug Delivery Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2026. This report will assist in analyzing the current and future business trends, sales and revenue forecasts. The recent research report on the global Liposomes Drug Delivery market presents the